$1.09 Billion is the total value of GREAT POINT PARTNERS LLC's 43 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDCO | New | The Medicines Companycall | $50,000,000 | – | 1,000,000 | +100.0% | 4.59% | – |
| PEN | New | PENUMBRA INC | $40,347,000 | – | 300,000 | +100.0% | 3.71% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $38,707,000 | – | 2,125,000 | +100.0% | 3.56% | – |
| ASND | New | ASCENDIS PHARMA AScall | $38,528,000 | – | 400,000 | +100.0% | 3.54% | – |
| UTHR | New | UNITED THERAPEUTICS CORP | $37,483,000 | – | 470,000 | +100.0% | 3.44% | – |
| DXCM | New | DEXCOM, INC | $22,575,000 | – | 151,264 | +100.0% | 2.07% | – |
| IONS | New | IONIS PHARMACEUTICALS, INC. | $16,176,000 | – | 270,000 | +100.0% | 1.49% | – |
| TNDM | New | TANDEM DIABETES CARE, INC. | $14,745,000 | – | 250,000 | +100.0% | 1.35% | – |
| ZGNX | New | ZOGENIX, INC.call | $10,010,000 | – | 250,000 | +100.0% | 0.92% | – |
| ALLK | New | ALLAKOS, INC. | $9,829,000 | – | 125,000 | +100.0% | 0.90% | – |
| SILK | New | SILK ROAD MEDICAL INC | $9,823,000 | – | 301,979 | +100.0% | 0.90% | – |
| TPTX | New | TURNING POINT THERAPEUTICS, INC. | $8,356,000 | – | 222,222 | +100.0% | 0.77% | – |
| ABEO | New | ABEONA THERAPEUTICS INC | $7,312,000 | – | 3,235,601 | +100.0% | 0.67% | – |
| ATRA | New | ATARA BIOTHERAP | $7,060,000 | – | 500,000 | +100.0% | 0.65% | – |
| EXEL | New | EXELIXIS, INC | $5,477,000 | – | 309,700 | +100.0% | 0.50% | – |
| AXSM | New | Axsome Therapeutics, Inccall | $4,048,000 | – | 200,000 | +100.0% | 0.37% | – |
| MYOV | New | MYOVANT SCIENCES LTD | $1,690,000 | – | 325,000 | +100.0% | 0.16% | – |
| OPK | New | OPKO HEALTH INC | $193,000 | – | 92,140 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.